Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR–ABL kinase domain mutations affect patient survival? First multicenter Argentinean study

References

• Daley GQ, Van Etten RA, Baltimore D. Introduction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824–830.
   PubMed Web of Science ®Google Scholar
• Elefanty AG, Hariharan IK, Cory S. BCR-ABL, the hallmark of chronic myeloid leukemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990;9:1069–1078.
   PubMed Web of Science ®Google Scholar
• Atallah E, Cortes J. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. Curr Opin Hematol 2007;14:138–144.
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Hahn EA, Sorensen MV, Druker BJ, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus cytarabine: results from the IRIS study. J Clin Oncol 2003;21:2138–2146.
   PubMed Web of Science ®Google Scholar
• Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Lett 2007;249:121–132.
   PubMed Web of Science ®Google Scholar
• Waller CF. Imatinib mesylate. Recent Results Cancer Res 2010;184:3–20.
   PubMedGoogle Scholar
• Mahon FX, Deininger, MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanism of resistance. Blood 2000;96: 1070–1079.
   PubMed Web of Science ®Google Scholar
• Chen Y, Peng C, Li D, Li S. Molecular and cellular bases of chronic myeloid leukemia. Protein Cell 2010;1:124–132.
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, et al. Abl mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100–4109.
   PubMed Web of Science ®Google Scholar
• le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95: 1758–1766.
   PubMed Web of Science ®Google Scholar
• Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is over-expressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006;108:1370–1373.
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–3745.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin A, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI 571) therapy. Leukemia 2002;16:2190–2196.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Eide CA, Deininger M. Bcr-Abl kinase domain mutations, drug resistance and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–2249.
   PubMed Web of Science ®Google Scholar
• Cang S, Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008;1:15.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The Word Health Organization (WHO) classification of myeloid neoplasms. Blood 2002;100:2292–2302.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Deininger MW, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.
   PubMed Web of Science ®Google Scholar
• Gorre M, Mansoor M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1965;53;457–481.
   Google Scholar
• Cox DR. Regression models and life tables. J R Stat Soc 1972;34;187–220.
   Google Scholar
• Nardi V, Azam M, Daley CQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004;11:35–43.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al. Detection of BCR/ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance and mutations in the ATP phosphate-binding (P-loop) are associated with a poor prognosis. Blood 2003;102:276–283.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Garg RJ, Kantarjian H, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the ‘best’ therapy? Curr Oncol Rep 2010;12:302–313.
   PubMedGoogle Scholar
• Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positve acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472–3475.
   PubMed Web of Science ®Google Scholar
• Shah N, Nicoll J, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibidor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2: 117–125.
   PubMed Web of Science ®Google Scholar
• Sharma P, Mohanty S, Kochupillai V, Kumar L. Mutations in ABL kinase domain are associated with inferior progression-free survival. Leuk Lymphoma 2010;51:1072–1078.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR/ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767–1773.
   PubMed Web of Science ®Google Scholar
• Roche-Lestienne C, Soenen-Cornu V, Grandel-Duflos N, et al. Several types of mutations of the ABL gene can be found in chronic myeloid leukemia patients resistant to STI571 and they can pre-exist to the onset of treatment. Blood 2002;100:1014–1018.
   PubMed Web of Science ®Google Scholar
• Kreuzer K, Le Coutre P, Landt O. et al. Preexistence and evolution of imatinib mesylate resistant clones in chronic myelogenous leukemia detected by PNA-based PCR clamping technique. Ann Hematol 2003;82:284–289.
   PubMed Web of Science ®Google Scholar
• Ernst T, Gruber F, Pelz Ackermann O, et al. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second line dasatinib or nilotinib therapy after failure of imatinib. Haematologica 2009;94:1227–1235.
   PubMed Web of Science ®Google Scholar
• Gambacorti Paaserini C, Gunby R, Piazza C, Galieta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75–85.
   PubMed Web of Science ®Google Scholar